Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
Albert Grinshpun(Harvard University), Rinath Jeselsohn(Harvard University)
Cited by 4
Related Papers
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
|Clinical Cancer Research|2024|34